Array ( [0] => Applebot/0.1 [1] => facebookexternalhit/1.1 [2] => LinkedInBot/1.0 [3] => meta-externalagent/1.1 [4] => Amazonbot/0.1 [5] => BLEXBot/1.0 [6] => DotBot/1.2 [7] => Qwantbot/1.0_1997801 [8] => AhrefsBot/7.0 [9] => DataForSeoBot/1.0 [10] => MatchorySearch/1.3 [11] => WRTNBot/1.0 [12] => Sogou web spider/4.0 [13] => MojeekBot/0.11 [14] => Yeti/1.1 [15] => SeznamBot/4.0 [16] => SemrushBot-SI/0.97 [17] => MistralAI-User/1.0 [18] => Qwantbot/1.0 [19] => coccocbot-web/1.0 [20] => coccocbot-image/1.0 [21] => PlagAwareBot/3.2 [22] => Barkrowler/0.9 [23] => AwarioSmartBot/1.0 [24] => PetalBot [25] => archive.org_bot [26] => Iframely/1.3.1 [27] => LogRocket-AssetCacher [28] => Slackbot 1.0 [29] => node-fetch/1.0 [30] => MJ12bot/v1.4.8 [31] => MJ12bot/v2.0.0 [32] => Timpibot/0.9 [33] => AwarioBot/1.0 [34] => MJ12bot/v2.0.1 [35] => Qwantbot/1.0_2850318 [36] => SiteAuditBot/0.97 [37] => Scrapy/2.11.2 [38] => CCBot/2.0 [39] => MJ12bot/v2.0.2 [40] => Scrapy/2.13.3 [41] => WordPress/6.8.3 [42] => MJ12bot/v2.0.4 [43] => SemrushBot/7~bl [44] => Qwairy-Bot/1.0 [45] => Embedly/0.2 [46] => GeedoProductSearch [47] => SemrushBot [48] => vkShare [49] => inkrich [50] => Discordbot/2.0 [51] => IbouBot/1.0 [52] => trafilatura/1.6.3 [53] => AnsehnBot/1.0 [54] => WP-URLDetails/6.8.3 [55] => HubSpot Crawler [56] => ShapBot/0.1.0 [57] => udu/1.6.5 [58] => aiohttp/3.13.1 [59] => l9scan/2.0 [60] => Trident/5.0 [61] => SmartBotCrawler/1.0 [62] => ) The user agent is not in the allowed list.Array ( [0] => pingbot/2.0 [1] => Googlebot/2.1 [2] => ChatGPT-User/1.0 [3] => PerplexityBot/1.0 [4] => OAI-SearchBot/1.0 [5] => GPTBot/1.2 [6] => Perplexity-User/1.0 [7] => YandexBot/3.0 [8] => YandexFavicons/1.0 [9] => AdsBot-Google-Mobile [10] => AdsBot-Google [11] => Gemini-Deep-Research [12] => DuckAssistBot/1.1 [13] => DuckDuckBot/1.1 [14] => GoogleOther [15] => YandexRenderResourcesBot/1.0 [16] => YandexImages/3.0 [17] => DuckAssistBot/1.2 [18] => Baiduspider/2.0 [19] => Baiduspider-render/2.0 [20] => bingbot/2.0 [21] => YandexUserproxy [22] => Pingdom.com_bot_version_1.4_ [23] => GPTBot/1.3 [24] => PingdomPageSpeed/1.0 [25] => YandexMobileBot/3.0 [26] => OAI-SearchBot/1.3 [27] => ClaudeBot/1.0 [28] => OAI-SearchBot/1.3 [29] => ) The user agent is an allowed/known agent.
Immunoassay Market Size & Growth Forecast 2026–2035, By Segments (Product, Specimen, End-use, Technology, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Base Year Value (2025)
USD 29.68 Billion
CAGR (2026-2035)
3.8%
Forecast Year Value (2035)
USD 43.1 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035
Key Takeaways
- North America region held more than 43.3% market share in 2025, attributed to advanced diagnostics and personalized medicine.
- Asia Pacific region will witness around 5.5% CAGR between 2026 and 2035, on account of rising chronic disease testing demand.
- With a share of 58.8% in 2025, reagents & kits segment’s dominance was secured by high usage drives reagents dominance.
- Achieving 58.8% immunoassay market share in 2025, the growth of blood segment was underpinned by diagnostic reliability drives blood dominance.
- The hospitals segment accounted for 41.2% of the immunoassay market in 2025, driven by high patient volume drives hospital dominance.
- Leading organizations shaping the immunoassay market include Roche (Switzerland), Abbott (USA), Siemens Healthineers (Germany), Beckman Coulter (USA), bioMérieux (France), Thermo Fisher Scientific (USA), DiaSorin (Italy), QIAGEN (Germany), Becton Dickinson (USA), Ortho Clinical Diagnostics (USA).
Market Growth Drivers and Industry Trends
Increasing adoption of precision medicine driving biomarker-based immunoassay testing demandAs treatment decisions become more tightly linked to molecular and protein-level patient profiles, healthcare providers are relying more heavily on biomarker detection to guide diagnosis, therapy selection, and response monitoring. This is strengthening demand in the immunoassay market because immunoassays offer a practical route for measuring clinically relevant biomarkers with the sensitivity, workflow compatibility, and throughput needed in routine care settings. The shift toward precision medicine is also influencing purchasing decisions by laboratories and hospital networks, which are prioritizing assay platforms that support broader biomarker menus, faster validation of new tests, and easier integration into disease-specific clinical pathways.
Rising prevalence of cancer and autoimmune disorders accelerating advanced diagnostic assay utilization
Growing clinical burden from cancer and autoimmune disorders is increasing the frequency and complexity of diagnostic workups, pushing providers toward assays that can detect disease-associated proteins, antibodies, and other immune-related markers with greater consistency. In the immunoassay market, this translates into stronger utilization of advanced assay formats for early detection, differential diagnosis, patient stratification, and longitudinal monitoring, especially where disease progression and treatment effects must be tracked over time. Demand is also being reinforced by the chronic and recurrent nature of many of these conditions, which supports repeat testing volumes and encourages laboratories to expand specialized immunodiagnostic capabilities.
Expanding point-of-care immunodiagnostics increasing decentralized testing capabilities across healthcare systems
The spread of point-of-care immunodiagnostics is shifting testing activity closer to patients, allowing hospitals, clinics, emergency settings, and outpatient care providers to obtain clinically actionable results without depending entirely on centralized laboratories. This is supporting expansion of the immunoassay market by increasing adoption of compact, rapid, and user-friendly assay platforms that fit decentralized workflows and shorten time to treatment decisions. As healthcare systems place greater emphasis on care delivery speed, patient throughput, and access in non-laboratory settings, vendors that can offer reliable immunoassay performance in distributed environments are gaining stronger commercial traction.
Regional Demand Dynamics
Largest Region
North America
50.24% Market Share in 2025
North America held the leading regional position in the immunoassay market in 2025, accounting for a 50.24% share. This leadership is sustained by the region’s established diagnostic infrastructure, broad use of immunoassay platforms across hospitals and clinical laboratories, and consistent testing volumes across routine screening, infectious disease detection, and chronic disease monitoring. Market activity is strengthened by the practical advantage of integrated laboratory workflows, where automated systems, trained personnel, and established reimbursement pathways support regular test utilization and replacement demand for instruments and consumables.
Asia Pacific is projected to expand at a 4.33% CAGR over the forecast period in the immunoassay market, backed by rising diagnostic adoption across a wider base of healthcare settings. Growth is being fueled by the expansion of laboratory capacity, increasing access to testing in developing healthcare systems, and stronger uptake of immunoassay methods as providers broaden disease detection and monitoring capabilities. As hospitals and diagnostic centers add testing volumes and modernize workflows, demand is accelerating through both new instrument installations and higher recurring use of assay kits.
| Regional Market Attractiveness & Strategic Fit Matrix | |||||
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub | Advanced | Developing | Advanced | Developing | Nascent |
| Cost-Sensitive Region | Low | Medium | Low | High | High |
| Regulatory Environment | Restrictive | Neutral | Restrictive | Neutral | Neutral |
| Demand Drivers | Strong | Strong | Strong | Moderate | Weak |
| Development Stage | Developed | Developing | Developed | Emerging | Emerging |
| Adoption Rate | High | Medium | High | Low | Low |
| New Entrants / Startups | Dense | Moderate | Dense | Sparse | Sparse |
| Macro Indicators | Strong | Stable | Stable | Weak | Weak |
No card data available for this language/report.
Segment Leadership and Growth Trends
Reagents & Kits held a 64.12% share of the immunoassay market in 2025, reflecting their central role in routine diagnostic workflows and research testing. Demand stays concentrated in this segment because every immunoassay run depends directly on assay-specific consumables, making procurement continuous rather than occasional. Their leadership is also supported by the installed base of immunoassay instruments, which creates recurring replacement cycles for compatible reagents and kits across clinical laboratories, hospitals, and diagnostic settings.
Software & Services is emerging as the fastest-growing product area in the immunoassay market as laboratories place greater emphasis on workflow efficiency, data handling, and system integration. Growth is being driven by the practical need to manage rising testing volumes with better automation, interpretation support, and connectivity to broader laboratory information environments. Compared with hardware-tied consumables, software and service offerings gain momentum as users seek to improve operational performance from existing immunoassay infrastructure without relying solely on new instrument purchases.
Specimen Segment Analysis: Blood (Largest Segment) vs Urine (Fastest-Growing Segment)
By 2025, Blood accounted for a 44.03% share of the immunoassay market, maintaining its lead because it remains the standard specimen type for a broad range of diagnostic and monitoring applications. Its position is sustained by strong clinical familiarity, established collection practices, and the wide validation of blood-based immunoassay protocols across healthcare settings. This consistent use in both routine and specialized testing keeps blood at the center of immunoassay demand.
Urine is the fastest-growing specimen segment in the immunoassay market due to its practicality in screening environments that require simple, non-invasive sample collection. Its momentum is supported by settings where ease of handling, faster collection logistics, and reduced procedural burden matter more relative to blood-based testing. As testing programs look for specimen options that can improve convenience and expand access, urine is gaining ground faster than alternative specimen types.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| Product | Reagents & Kits, Analyzers/Instruments, Software & Services | Reagents & Kits | Software & Services |
| Specimen | Blood, Saliva, Urine, Others | Blood | Urine |
| End-use | Hospitals, Blood Banks, Clinical Laboratories, Pharmaceutical and Biotech Companies, Academic Research Centers, Others | Hospitals | Clinical Laboratories |
| Technology | Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), Chemiluminescence Immunoassays (CLIA), Fluorescence Immunoassays (FIA), Rapid Test, Others | Enzyme Immunoassays (EIA) | Rapid Test |
| Application | Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease Testing, Autoimmune Diseases, Others | Infectious Disease Testing | Oncology |
Read our Research ApproachCompetitive Landscape and Market Positioning
Company Profile
Business Overview Financial Highlights Product Landscape SWOT Analysis Recent Developments Company Heat Map Analysis
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Danaher Corporation (United States)
5. Thermo Fisher Scientific Inc. (United States)
6. bioMérieux SA (France)
7. Becton Dickinson and Company (United States)
8. Sysmex Corporation (Japan)
9. Bio-Rad Laboratories Inc. (United States)
10. QuidelOrtho Corporation (United States)
The immunoassay market is experiencing rapid innovation driven by demand for highly sensitive and automated diagnostic solutions. Companies are introducing advanced assay platforms that support faster detection, multiplex testing, and improved clinical accuracy across healthcare applications. Increased integration of automation and digital analysis tools is further strengthening efficiency and competitiveness within the immunoassay market.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| ARCHIMED Diagnostics | Oct-25 | ARCHIMED Diagnostics acquired ARK Diagnostics in a transaction valued at $428 million. This acquisition expands the firm's specialty immunoassay in vitro diagnostics portfolio and strengthens its underlying diagnostics platform capabilities. |
| bioMérieux | Jan-25 | bioMérieux acquired SpinChip Diagnostics ASA, securing a point-of-care immunoassay platform capable of delivering diagnostic results within ten minutes. This integration significantly bolsters the company’s rapid diagnostics portfolio and point-of-care market position. |
| QuidelOrtho Corporation | Feb-26 | QuidelOrtho entered a strategic supply agreement with Lifotronic Technology to expand its global immunoassay portfolio with new analyzer platforms and over 25 assays. The partnership enhances its high-throughput diagnostic offerings and scales commercial reach across Europe, Asia-Pacific, Latin America, and the Middle East & Africa. |
| Spear Bio | Aug-25 | Spear Bio established a strategic distribution partnership with Bio-Techne to accelerate the commercialization of its next-generation, ultrasensitive immunoassay technology. The collaboration targets both life science research and clinical diagnostics sectors to drive the adoption of its proprietary platform. |
| MeMed | Apr-26 | MeMed received CE Mark approval for its rapid host-response test, which differentiates between bacterial and viral infections in approximately 20 minutes. This regulatory milestone supports the integration of sophisticated immunoassay-based diagnostic solutions into routine clinical workflows. |
| Fujirebio | Jan-26 | Fujirebio launched the Lumipulse G pTau 217 CSF assay for its automated LUMIPULSE G analyzers. This development expands chemiluminescent enzyme immunoassay-based neurological testing capabilities, addressing the growing demand for automated, high-throughput biomarker measurement in Alzheimer’s disease research and diagnostics. |
| Siemens Healthineers | Dec-25 | Siemens Healthineers partnered with ALZpath to integrate the pTau217 antibody into a new in vitro diagnostic assay for Alzheimer’s disease. This strategic collaboration strengthens the company’s neurodegenerative disease immunoassay portfolio and advances its capability to provide standardized biomarker testing. |
| Quanterix Corporation | Jun-25 | Quanterix secured Class 1 Medical Device registration in South Korea for its HD-X Simoa Immunoassay Analyzer. This regulatory approval facilitates the expansion of its ultra-sensitive immunoassay platform within the Asia-Pacific region, increasing market access for advanced protein analysis. |
| T&D Diagnostics | Apr-25 | T&D Diagnostics commenced domestic manufacturing of its Starkwert FIA product range in India. This investment in local production capabilities enhances the company's ability to supply fluorescence immunoassay diagnostic solutions to the regional market. |
| Anbio Biotechnology | Jan-25 | Anbio Biotechnology launched the ADL-1000, a Dry Chemiluminescence Immunoassay solution featuring freeze-dried reagents and whole-blood testing. The system is designed to streamline laboratory workflows and reduce costs, expanding the application of chemiluminescence diagnostics across infectious, cardiovascular, and neurological disease testing. |
Frequently Asked Questions
What is the current size of the immunoassay market?
The market revenue for immunoassay is anticipated at USD 30.64 billion in 2026.
How much is the immunoassay industry expected to grow by 2035?
Immunoassay Market size is projected to expand significantly moving from USD 29.68 billion in 2025 to USD 43.1 billion by 2035 with a CAGR of 3.8% during the 2026-2035 forecast period.
How is precision medicine influencing demand in the immunoassay market?
Precision medicine is increasing demand for biomarker-based immunoassays as healthcare providers and laboratories seek platforms that support disease-specific testing, therapy selection, response monitoring, and efficient integration into clinical workflows.
Why are point-of-care immunodiagnostics gaining commercial traction in the immunoassay market?
Decentralized testing enables hospitals and outpatient providers to deliver faster clinical decisions using compact, user-friendly immunoassay platforms that improve patient throughput and expand diagnostic access beyond centralized laboratories.
Why do Reagents & Kits account for the largest share of the immunoassay market?
Reagents & Kits held a 64.12% share in 2025 because every immunoassay test requires consumables, creating recurring procurement demand across laboratories, hospitals, and diagnostic facilities.
Which specimen type is growing fastest in the immunoassay market?
Urine is the fastest-growing specimen segment, driven by its non-invasive collection process, ease of handling, and suitability for screening programs seeking greater convenience and accessibility.
Why does North America dominate the immunoassay market?
North America held a 50.24% market share in 2025, supported by advanced diagnostic infrastructure, automated laboratory workflows, established reimbursement systems, and consistently high testing volumes.
What is accelerating immunoassay market growth in Asia Pacific?
Asia Pacific is projected to grow at a 4.33% CAGR as laboratory capacity expands, diagnostic access improves, and healthcare providers increase adoption of immunoassay testing for disease detection and monitoring.
Who are the leading players in the immunoassay landscape?
Top players in the immunoassay market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), bioMérieux SA (France), Becton, Dickinson and Company (United States), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (United States), QuidelOrtho Corporation (United States).
Our Clients
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
